Does CPHI pay a dividend and is it safe?

China Pharma Holdings Inc. (CPHI) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / CPHI / dividends

ABVC (32) BCTX (40) BYSI (37) RNAZ (35) ⌘ Pro Terminal →

China Pharma Holdings Inc. (CPHI) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is CPHI trading relative to its 50-day, 200-day, and 52-week technical levels?

CPHI last traded at $0.61 (-2.98% on volume of 105,409 shares), positioning the stock -17.57% below its 50-day simple moving average ($0.74) and -25.61% below its 200-day simple moving average ($0.82). Across its 52-week range of $0.38 to $19.19, CPHI sits at the 1.2% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.69).

$0.61 -2.98% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.61

China Pharma Holdings Inc. (CPHI) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $26.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CPHI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CPHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, China Pharma Holdings Inc. (NYSE: CPHI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.61 (-2.98% 1D, market cap $26.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CPHI ranks #606 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CPHI compare to ABVC and BCTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPHI carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of -3.2%, and ROIC of -11.4%. By comparison, ABVC (ABVC BioPharma Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M). Among the 5-stock peer group, CPHI leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CPHI?

▼

Per CPHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001106644), China Pharma Holdings Inc. generated $4.1M in revenue (-8.5% YoY), -$3.2M in net income, and $88.9K in free cash flow against $31.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.61 (-0.73%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 2.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CPHI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY CPHI SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.75-4% Next Q

Q2 (-2Q)

Grade D$0.72-12.5% Next Q

Q3 (-1Q)

Grade E$0.63-3.2% Next Q

Current

Grade D-$0.61-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CPHI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CPHI currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.74) and Max Pain ($0.64) forces dealer call-delta covering toward $20.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CPHI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CPHI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPHI)

✓Walkthrough of CPHI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CPHI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.31%⚡ TESTING RESISTANCE

2026-11-03O $0.65H $0.65L $0.61C $0.61VOL 184.3K

RES: $1.25SUP: $0.60SMA50: $0.74SMA200: $0.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CPHI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CPHI Butterfly Map → + Track CPHI →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -8.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CPHI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CPHI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CPHI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPHI)

Health Care Rank #606 of 1015 ⚔️ ABVC vs CPHI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CPHI vs. ABVC, BCTX, BYSI, RNAZ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, China Pharma Holdings Inc. (CPHI) ranks #606 by composite RQD confidence (35/100, grade D-) and #808 by equity capitalization ($26.9M). Within this direct 5-issuer industry benchmark cohort, CPHI leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with CPHI at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CPHI ACTIVE China Pharma Holdings Inc.	D-	35/100	—	-3.2%	-11.4%	-2.98%	$26.9M	Benchmark Subject
ABVC ABVC BioPharma Inc.	E	32/100	—	—	-35.0%	-1.99%	$26.7M	/abvc-vs-cphi →
BCTX BriaCell Therapeutics Corp.	D-	40/100	—	—	—	+1.65%	$26.5M	/bctx-vs-cphi →
BYSI BeyondSpring Inc.	D-	37/100	—	—	-35.0%	+25.18%	$26.5M	/bysi-vs-cphi →
RNAZ TransCode Therapeutics Inc.	D-	35/100	—	—	-35.0%	0.00%	$27.6M	/rnaz-vs-cphi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001106644 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), China Pharma Holdings Inc. (CPHI) reported GAAP revenue of $4.1M (-8.5% vs. FY2024 revenue of $4.5M , and -40.9% cumulative change since FY2023) , GAAP net income of -$3.2M, operating cash flow of $148.3K, and free cash flow of $88.9K (+120.0% YoY). On the balance sheet, CPHI closed FY2025 with $31.0M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.1M	-$3.2M	$148.3K	$88.9K	$31.0M	—
FY2024 (FY)	2024-12-31	$4.5M	-$4.7M	-$406.1K	-$444.5K	$14.9M	—
FY2023 (FY)	2023-12-31	$7.0M	-$3.1M	-$699.7K	-$699.7K	—	—

3. CPHI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CPHI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CPHI compare to ABVC and BCTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CPHI?

Where is CPHI trading relative to its 50-day, 200-day, and 52-week technical levels?

CPHI last traded at $0.61 (-2.98% on volume of 105,409 shares), positioning the stock -17.57% below its 50-day simple moving average ($0.74) and -25.61% below its 200-day simple moving average ($0.82). Across its 52-week range of $0.38 to $19.19, CPHI sits at the 1.2% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.69).

Direct Sub-Reports: CPHI RQD Cockpit CPHI 12M Forecast CPHI Earnings & Move CPHI Dividends & DRIP CPHI Insiders & 13F CPHI Whale Options CPHI Profit Sankey CPHI News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CPHI — China Pharma Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

China Pharma Holdings Inc. (CPHI) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.61 (-2.98% 1D, market capitalization $26.9M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -11.4%, gross margin of -3.2%, operating margin of -60.0%, and free cash flow yield of 0.32%.
Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

China Pharma Holdings Inc. Is a NYSE-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations..0B on a rounded basis, consistent with the $28.0M figure in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), China Pharma Holdings Inc. (CPHI) reported $4.1M in annual revenue (up from $4.5M in FY2024, -8.5% YoY) and -$3.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.0M revenue, -$3.1M net income) through FY2025, CPHI scaled operating cash flow to $148.3K and free cash flow to $88.9K, backed by $31.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.32% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.38 – $19.19 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — Investors should note that the absence of mapped links means the source data cannot identify which suppliers, customers, or peers would transmit shocks to CPHI.

Key Question #1: Can CPHI sustain or expand its -60.0% operating margin and -11.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.1M and free cash flow of $88.9K, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CPHI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CPHI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for China Pharma Holdings Inc. (CPHI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CPHI Debate Forum (3) ↓

🟡 MARKET WIRE ChartMill • 1d ago

On Thursday, there are stocks with unusual volume. Let's take a look.

ChartMill report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

China Pharma Holdings, Inc. Estimates – AMEX:CPHI

TradingView report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A December 22 vote will decide a reverse-split limit for China Pharma (NYSE: CPHI).

Stock Titan report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's After-Market Session - Biomea Fusion (NASDAQ:BMEA), iTonic Holdi

Benzinga report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST ChartMill • 1d ago

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

ChartMill report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

RNAZ Stock Price, Quote & News

Syfe report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 2d ago

China Pharma Holdings (CPHI) Slips 2.67% to $0.66, Drifting Toward $0.63 Support - Delta Hedging

https://www.siam.in/ report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 2d ago

CPHI Q3 2011 Earnings: EPS Misses Estimate as Stock Declines 6.04% - Earnings Per Share

https://www.dars.gov.et/ report covering China Pharma Holdings Inc. (CPHI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CPHI Bull vs. Bear Conversation Board — What's Your Call at $0.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CPHI 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.81 (+30.6%)

📌 Pinned Debate

The stock trades at $0.65 with a $28.0M market cap, far below its prior 52-week high of $19.19, leaving room for recovery if the busine

Here is why I am bullish on CPHI here at $0.62: The stock trades at $0.65 with a $28.0M market cap, far below its prior 52-week high of $19.19, leaving room for recovery if the business stabilizes.. Compare CPHI's -60.0% operating margin and -11.4% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $0.59 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — CPHI's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $0.51 (-17.7%)

Spot @ $0.62

With an Altman Z-Score of 0.2, ROIC of -11.4%, and net margin of -60%, the company shows severe financial distress with no reported pat

Sitting on the sidelines or leaning short CPHI above $0.62. With an Altman Z-Score of 0.2, ROIC of -11.4%, and net margin of -60%, the company shows severe financial distress with no reported path to profitability.. Until Fundamental Cash Engine (6/20) and FCF yield (0.32%) inflect higher, upside is capped near $19.19.